Corporate Responsibility
March 16, 2022
Alnylam Publishes 2021 Corporate Responsibility Report
We're committed to taking bold actions that improve the health of humanity. Our 2021 Corporate Responsibility Report provides details on our progress...
Read More ›
December 21, 2021
Alnylam Publishes 2021 Patient Access Philosophy Report
Alnylam has published its 2021 Patient Access Philosophy Report detailing its actions as a company to provide access to its medicines for those who may...
Read More ›
October 13, 2021
Alnylam Challengers - a Health Equity Community Impact Program
Alnylam Challengers is Alnylam's signature CSR Community Impact Program. It aims to improve health access to underserved communities.
Read More ›
March 11, 2021
Alnylam Publishes First Corporate Responsibility Summary
Today, we've published Alnylam's first Corporate Responsibility Summary detailing our approach to corporate responsibility and the actions we are and intend...
Read More ›
December 7, 2020
Alnylam Releases 2nd Annual Patient Access Philosophy Report
The 2020 Alnylam Patient Access Philosophy Report details Alnylam's progress against key metrics related to patient access to its innovative RNAi therapeutics.
Read More ›
October 1, 2020
A New European Biotech Social Pact
The European Pact builds on Alnylam’s own pledge, encouraging biotech companies to be a force for good in partnering with European authorities, citizens and...
Read More ›
June 24, 2020
Celebrating a Pride Month Unlike Any Other
We asked members of our SAGA (Sexuality and Gender Alliance) employee resource network (ERN) how they've been celebrating Pride this year, given the...
Read More ›
June 1, 2020
We Stand Against All Forms of Racism and Discrimination
On June 1, 2020, we issued the following public statement in response to events unfolding in the United States as a result of the killing of George Floyd...
Read More ›
